Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation (NCT00003538) | Clinical Trial Compass
CompletedNot Applicable
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
United StatesStarted 1997-03
Plain-language summary
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. Stem cells that have been treated in the laboratory to remove lymphocytes may prevent this from happening.
PURPOSE: Clinical trial to prevent graft-versus-host disease in patients undergoing bone marrow transplantation.
Who can participate
Age range65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed diagnosis of one the following:
* Acute myelogenous leukemia in CR1, ER1, CR2, ER2, CR3
* Acute lymphocytic leukemia in CR1, ER1, CR2, ER2, CR3
* Non-Hodgkin's lymphoma
* Hodgkin's lymphoma
* Multiple myeloma with no more than 12 months of prior alkylator based chemotherapy
* Myelodysplastic syndrome (MDS)
* Acute leukemia arising out of MDS
* Primary resistant acute leukemia
* Chronic myelomonocytic leukemia
* Aplastic anemia (40 years of age and over)
* Solid tumor malignancy (germ cell, sarcoma, breast, etc.)
* Genetic disorders or inborn errors of metabolism as defined by preparative regimen protocol
* Chronic myelogenous leukemia
* Must meet all inclusion criteria specified by the respective preparative regimen protocol
* No aplastic anemia under 40 years of age or myelofibrosis
PATIENT CHARACTERISTICS:
Age:
* 0.5 to 65
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* No prior red blood cell or platelet transfusions from a sibling donor
Chemotherapy:
* Not specified
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* Not specified
Trial details
NCT IDNCT00003538
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins